Volume 5.07 | Feb 28

Prostate Cell News 5.07 February 28, 2014
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
GPX2 Overexpression Is Involved in Cell Proliferation and Prognosis of Castration Resistant Prostate Cancer
Researchers investigated the role of glutathione peroxidase 2 (GPX2) in castration resistant prostate cancer (CRPC). GPX2 expression was analyzed in rat and human CRPC cells. [Carcinogenesis] Abstract
FREE ALDEFLUOR™ Protocol Optimization Resource Pack – Get Yours
PUBLICATIONS (Ranked by impact factor of the journal)

SNAI1 Is Critical for the Aggressiveness of Prostate Cancer Cells with Low E-Cadherin
Researchers examined the role of two epithelial-to-mesenchymal transition regulators, the adherens junction protein E-cadherin and its transcriptional repressor SNAI1, in regulating the aggressiveness of prostate cancer cells. [Mol Cancer] Abstract | Full Article

Androgen Receptor Promotes the Oncogenic Function of Overexpressed Jagged1 in Prostate Cancer by Enhancing Cyclin B1 Expression via Akt Phosphorylation
Androgen receptor was found to promote the oncogenic function of Jagged1 to enhance cell proliferation rate by comparing four prostate cancer cell lines, LNCaP, LAPC4, DU145 and PC3. [Mol Cancer Res] Abstract

Preclinical Pharmacology of FL442, a Novel Nonsteroidal Androgen Receptor Modulator
The preclinical profiles of two potent compounds of recently published cycloalkane[d]isoxazole pharmacophore-based androgen receptor (AR) modulators, FL442 and its nitro analog FL425, were explored to evaluate their druggability for the treatment of AR dependent prostate cancer. [Mol Cell Endocrinol] Abstract

Identification of an Anabolic Selective Androgen Receptor Modulator that Actively Induces Death of Androgen-Independent Prostate Cancer Cells
Researchers screened 3000 selective androgen receptor (AR) modulators for the ability to arrest the androgen-independent growth of AR(+) 22Rv1 and LNCaP prostate cancer cells but not AR(-) PC3 or DU145 cells. [J Steroid Biochem Mol Biol] Abstract

Pomegranate Extracts Impact the Androgen Biosynthesis Pathways in Prostate Cancer Models In Vitro and In Vivo
Scientists investigated the effects of pomegranate extracts and their ability to inhibit androgen biosynthesis using prostate cancer cell lines in vitro as well as the PTEN knockout mouse model representing prostate cancer. [J Steroid Biochem Mol Biol] Abstract

Apigenin Induces Apoptosis by Targeting Inhibitor of Apoptosis Proteins and Ku70-Bax Interaction in Prostate Cancer
Treatment of androgen-refractory human prostate cancer PC-3 and DU145 cells with apigenin resulted in dose-dependent suppression of XIAP, c-IAP1, c-IAP2 and survivin protein levels. [Apoptosis] Abstract

Shikonin Inhibits the Growth of Human Prostate Cancer Cells via Modulation of the Androgen Receptor
Researchers observed that shikonin decreased the expression of androgen receptor at both the mRNA and the protein levels in LNCaP and 22RV1 human prostate cancer cells. [Int J Oncol] Abstract

Zyflamend, a Polyherbal Mixture, Down Regulates Class I and Class II Histone Deacetylases and Increases p21 Levels in Castrate-Resistant Prostate Cancer Cells
CWR22Rv1 cells, a castrate-resistant prostate cancer cell line, were treated with Zyflamend and the expression of class I and II histone deacetylases, along with their downstream target the tumor suppressor gene p21, was investigated. [BMC Complement Altern Med] Abstract | Full Article


Baseline Selenium Status and Effects of Selenium and Vitamin E Supplementation on Prostate Cancer Risk
The Selenium and Vitamin E Cancer Prevention Trial found no effect of selenium supplementation on prostate cancer risk but a 17% increased risk from vitamin E supplementation. This case-cohort study investigates effects of selenium and vitamin E supplementation conditional upon baseline selenium status. [J Natl Cancer Inst] Abstract | Press Release

Serum Biomarkers of Bone Metabolism in Castration-Resistant Prostate Cancer Patients with Skeletal Metastases: Results from SWOG 0421
Researchers prospectively evaluated the prognostic and predictive value of bone biomarkers in sera from castration-resistant prostate cancer patients treated on a placebo-controlled Phase III trial of docetaxel with or without the bone targeted endothelin-A receptor antagonist atrasentan (SWOG S0421). [J Natl Cancer Inst] Abstract

ProstaCult™: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays - FREE Sample Request
The Proteomics of Prostate Cancer Exosomes
Structurally, prostate-derived exosomes are distinct in size, membrane composition and specific prostate protein content, potentially providing a novel and easily isolatable source of biomarkers from clinical biofluids. The key to these isolation strategies will be the targeting of specific prostatic proteins expressed in these exosomes, thus requiring detailed proteomic characterizations. [Expert Rev Proteomics] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Metamark Genetics Receives Laboratory License in Preparation to Launch ProMark™ Prostate-Cancer Assay
Metamark Genetics, Inc. announced that its Cambridge, Mass. laboratory has been licensed for the highest level of clinical testing in the use of ProMark™, the company’s prognostic assay to guide the medical management of patients with prostate cancer. [Metamark Genetics, Inc.] Press Release

Understanding and Tackling Prostate and Colorectal Cancer through Unlocking the Cancer’s DNA Code
With a large contribution of the Center for Translational Molecular Medicine, a new Dutch consortium will study the relationship between DNA aberrations and the development of both prostate and colorectal tumors. [Center for Translational Molecular Medicine] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW The Stem Cell Niche 2014
May 18-22, 2014
Copenhagen, Denmark

Visit our events page to see a complete list of events in the prostate cell community.
NEW Postdoctoral Training Fellow – Cancer Biology (Institute of Cancer Research)

NEW Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Postdoctoral Fellow – Prostate Cancer (Mayo Clinic- Rochester)

Postdoctoral Fellow – Biomarker Discovery In Prostate Cancer (University of California, San Francisco)

Postdoctoral Position – Cancer Biology/Genomics (Weill Cornell Medical College)

Experienced Researcher – Detection of Prostate Cancer Biomarkers (Dublin City University)

Postdoctoral Fellow – Role of Mitochondria in Cancer Progression (Baylor College of Medicine)

Postdoctoral Position – Prostate Cancer (Roswell Park Cancer Institute)

Postgraduate Position – Chemokine Receptor Induced Cell Migration (University of East Anglia)

Graduate Student Position – Epigenetics and Chromatin (University of Victoria)

Postdoctoral Fellow – Mechanism of Prostate Cancer Bone Metastasis (Georgia Regents University)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Prostate Cell News: Archives | Events | Contact Us